ID.1
Item
primary refractory or relapsed aml
boolean
C0278780 (UMLS CUI [1])
ID.2
Item
confirmed diagnosis of aml (de novo or secondary) as defined by who classification (vardiman 2002)
boolean
C0023467 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
ID.3
Item
aged at least 18 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance
Item
Does the subject have an Eastem Cooperative Oncology Group (ECOG) Performance Status (PS) greater than 2?
boolean
C1520224 (UMLS CUI [1])
ID.4
Item
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
boolean
C0023487 (UMLS CUI [1])
ID.5
Item
patient in blast crisis stage of chronic myeloid leukemia
boolean
C0919644 (UMLS CUI [1])
ID.6
Item
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
boolean
C0010711 (UMLS CUI [1])
ID.7
Item
interval of <6 months between first onset of last complete remission and current relapse
boolean
C0677874 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
ID.8
Item
those with primary refractory leukemia who have received more than three previous induction cycles
boolean
C0857127 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
ID.9
Item
relapsed patients who have received more than three previous treatment regimens
boolean
C0392920 (UMLS CUI [1])